What is the appropriate management of a hypertensive crisis, including how to differentiate and treat hypertensive emergency versus hypertensive urgency?

Hypertensive Crisis Management

Critical First Step: Differentiate Emergency from Urgency

The presence or absence of acute target-organ damage—not the blood pressure number—determines whether you have a hypertensive emergency requiring ICU admission with IV therapy, or a hypertensive urgency managed with oral agents and outpatient follow-up. 1, 2

Rapid Bedside Assessment for Target-Organ Damage (Complete Within Minutes)

Neurologic:

• Altered mental status, somnolence, lethargy, seizures, or coma suggesting hypertensive encephalopathy 1, 2
• Severe headache with vomiting, visual disturbances (cortical blindness), or focal neurologic deficits 1, 2
• Acute stroke (ischemic or hemorrhagic) 1, 2

Cardiac:

• Chest pain indicating acute myocardial ischemia or infarction 1, 2
• Dyspnea with pulmonary edema or acute left-ventricular failure 1, 2

Vascular:

• Sudden severe chest or back pain radiating posteriorly (aortic dissection) 1, 2

Renal:

• Acute rise in creatinine, oliguria, or new proteinuria 1, 2
• Thrombotic microangiopathy: thrombocytopenia with elevated LDH and low haptoglobin 2

Ophthalmologic (Malignant Hypertension):

• Bilateral retinal hemorrhages, cotton-wool spots, or papilledema (grade III-IV retinopathy) on fundoscopy 1, 2
• Note: Isolated subconjunctival hemorrhage is not acute target-organ damage 2

Obstetric:

• Severe preeclampsia or eclampsia 1, 2

---

Management of HYPERTENSIVE EMERGENCY (Target-Organ Damage Present)

Immediate Actions

• Admit to ICU with continuous arterial-line blood pressure monitoring (Class I recommendation) 1, 2, 3
• Initiate intravenous antihypertensive therapy immediately 1, 2, 3

Blood Pressure Reduction Targets

For Most Emergencies (No Compelling Condition):

• First hour: Reduce mean arterial pressure by 20–25% (or systolic ≤25%) 1, 2, 3
• Hours 2–6: Lower to ≤160/100 mmHg if stable 1, 2, 3
• Hours 24–48: Gradually normalize blood pressure 1, 2, 3
• Avoid systolic drops >70 mmHg—this precipitates cerebral, renal, or coronary ischemia, especially in chronic hypertensives with altered autoregulation 1, 2

Compelling Conditions Requiring More Aggressive Targets:

Condition	Target BP	Timeframe
Aortic dissection	SBP <120 mmHg	Within 20 minutes [1,2]
Severe preeclampsia/eclampsia or pheochromocytoma	SBP <140 mmHg	Within first hour [1,2]
Acute coronary syndrome or pulmonary edema	SBP <140 mmHg	Immediately [1,2]
Acute intracerebral hemorrhage (SBP ≥220 mmHg)	SBP 140–180 mmHg	Within 6 hours [1,2]
Acute ischemic stroke (BP >220/120 mmHg)	Reduce MAP by ~15%	Within first hour [1,2]

First-Line Intravenous Medications

NICARDIPINE (Preferred for Most Emergencies Except Acute Heart Failure):

• Dosing: Start 5 mg/h IV, titrate by 2.5 mg/h every 15 minutes to max 15 mg/h 1, 2, 3
• Advantages: Preserves cerebral blood flow, does not raise intracranial pressure, predictable titration, rapid onset (5–15 min), short duration (30–40 min) 1, 2, 3
• Avoid in: Acute heart failure (reflex tachycardia can worsen condition) 2, 3

LABETALOL (Preferred for Aortic Dissection, Eclampsia, Malignant Hypertension with Renal Involvement):

• Dosing: 10–20 mg IV bolus over 1–2 minutes, repeat/double every 10 minutes (max cumulative 300 mg) OR continuous infusion 2–8 mg/min 1, 2, 3
• Advantages: Dual α/β-blockade controls both BP and heart rate 1, 2, 3
• Contraindications: Reactive airway disease, COPD, heart block, bradycardia, decompensated heart failure 1, 2, 3

CLEVIDIPINE (Alternative Rapid-Acting CCB):

• Dosing: Start 1–2 mg/h IV, double every 90 seconds until near target, then increase <2-fold every 5–10 minutes; max 32 mg/h (limit to 72 hours) 1, 2
• Advantages: Ultra-short acting, extremely rapid titration 1, 2
• Contraindication: Soy/egg allergy 2

SODIUM NITROPRUSSIDE (Last-Resort Only):

• Dosing: 0.25–10 µg/kg/min IV infusion 1, 2
• Critical Safety: Co-administer thiosulfate when infusion ≥4 µg/kg/min or >30 minutes to prevent cyanide toxicity 2
• Use only when other agents fail 1, 2, 3

Condition-Specific IV Regimens

Acute Coronary Syndrome / Pulmonary Edema:

• Nitroglycerin 5–100 µg/min IV ± labetalol 1, 2, 3
• Avoid nicardipine monotherapy (reflex tachycardia worsens ischemia) 2, 3

Aortic Dissection:

• Esmolol loading 500–1000 µg/kg, then 50–200 µg/kg/min BEFORE any vasodilator 1, 2
• Add nitroprusside or nitroglycerin after beta-blockade to achieve SBP ≤120 mmHg and HR <60 bpm 1, 2

Eclampsia/Preeclampsia:

• Labetalol, hydralazine, or nicardipine 1, 2, 3
• Absolutely contraindicated: ACE inhibitors, ARBs, nitroprusside 1, 2, 3

Hypertensive Encephalopathy:

• Nicardipine preferred (preserves cerebral perfusion without raising ICP) 2
• Labetalol acceptable alternative 2

---

Management of HYPERTENSIVE URGENCY (No Target-Organ Damage)

Key Principle

Hospital admission and IV agents are NOT required; treatment is outpatient with oral antihypertensives. 1, 2, 4

Blood Pressure Reduction Strategy

• First 24–48 hours: Gradual reduction to <160/100 mmHg 1, 2, 4
• Subsequent weeks: Aim for <130/80 mmHg 1, 2, 4
• Avoid rapid BP lowering—this can cause cerebral, renal, or coronary ischemia in chronic hypertensives 1, 2, 4
• Up to one-third of patients with elevated BP normalize before follow-up; rapid lowering may be harmful 2, 4

Preferred Oral Agents

CAPTOPRIL (ACE Inhibitor):

• Dosing: 12.5–25 mg PO 2, 4
• Caution: Start at low dose in volume-depleted patients (risk of sudden BP drops from pressure natriuresis) 2, 4
• Contraindications: Pregnancy, bilateral renal artery stenosis 2

EXTENDED-RELEASE NIFEDIPINE (Calcium Channel Blocker):

• Dosing: 30–60 mg PO 2, 4
• NEVER use immediate-release nifedipine—causes unpredictable precipitous drops, stroke, and death 1, 2, 4

ORAL LABETALOL (Combined α/β-Blocker):

• Dosing: 200–400 mg PO 2, 4
• Contraindications: Same as IV formulation (reactive airway disease, heart block, bradycardia) 2, 4

Follow-Up

• Observe for at least 2 hours after medication administration to evaluate efficacy and safety 2, 4
• Outpatient visit within 2–4 weeks, then monthly until target BP achieved 1, 2, 4

---

Critical Pitfalls to Avoid

• Do NOT admit patients with severe hypertension without evidence of acute target-organ damage—this is urgency, not emergency 1, 2
• Do NOT use IV agents for hypertensive urgency—oral therapy is safer and appropriate 1, 2, 4
• Do NOT rapidly lower BP in urgency—may cause hypoperfusion injury 1, 2, 4
• Do NOT normalize BP acutely in chronic hypertensives—altered cerebral autoregulation predisposes to ischemic injury 1, 2
• Do NOT use immediate-release nifedipine—associated with stroke and death 1, 2, 4
• Do NOT treat the BP number alone—many patients with acute pain/distress have transient elevations that resolve when underlying cause is addressed 1, 2
• Do NOT assume absence of symptoms equals absence of organ damage—focused exam including fundoscopy is essential 2

---

Post-Stabilization Management

• Screen for secondary causes after stabilization—20–40% of malignant hypertension cases have identifiable etiologies (renal artery stenosis, pheochromocytoma, primary aldosteronism, renal parenchymal disease) 1, 2
• Address medication non-adherence—the most common trigger for hypertensive emergencies 1, 2
• Transition to oral regimen 24–48 hours after stabilization, typically combining RAS blocker, calcium channel blocker, and diuretic 2
• Monthly follow-up until target BP <130/80 mmHg achieved and organ damage regresses 1, 2

---

Prognosis

• Untreated hypertensive emergencies carry >79% one-year mortality and median survival of only 10.4 months 2
• Even with treatment, patients remain at markedly increased cardiovascular and renal risk compared to hypertensives without emergencies 2